Guideline for the use of immunobiologicals in chronic rhinosinusitis with nasal polyps (CRSwNP) in Brazil
Open Access
- 3 April 2021
- journal article
- review article
- Published by Elsevier BV in Brazilian Journal of Otorhinolaryngology
- Vol. 88 (3), 471-480
- https://doi.org/10.1016/j.bjorl.2021.03.003
Abstract
No abstract availableThis publication has 65 references indexed in Scilit:
- Omalizumab therapy for refractory allergic fungal rhinosinusitis patients with moderate or severe asthmaAmerican Journal of Otolaryngology, 2015
- Olfactory outcomes in chronic rhinosinusitis with nasal polyposis after medical treatments: a systematic review and meta‐analysisInternational Forum of Allergy & Rhinology, 2014
- Omalizumab in Asthma: An Update on Recent DevelopmentsThe Journal of Allergy and Clinical Immunology: In Practice, 2014
- Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumabJournal of Allergy and Clinical Immunology, 2014
- Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthmaJournal of Allergy and Clinical Immunology, 2012
- Mepolizumab, a humanized anti–IL-5 mAb, as a treatment option for severe nasal polyposisJournal of Allergy and Clinical Immunology, 2011
- A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitisRhinology journal, 2010
- Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE‐mediated) asthmaBritish Journal of Clinical Pharmacology, 2009
- OmalizumabTreatments in Respiratory Medicine, 2004
- Enhanced soluble interleukin‐5 receptor alpha expression in nasal polyposisAllergy, 2003